Efficacy of Lianhua Qingwen in Treating Patients Infected With the Omicron Variant of the COVID-19

Qianfoshan Hospital

Status

Enrolling

Conditions

COVID-19 Pneumonia

Treatments

Drug: The group of patients who received Lianhua Qingwen orally

Other: The group of patients who did not receive Lianhua Qingwen orally

Study type

Observational

Funder types

Other

Identifiers

NCT05778318

YXLL-KY-2022(095)

Details and patient eligibility

About

A retrospective analysis was conducted on patients infected with the Omicron variant of COVID-19 diagnosed from August 2022 to now. Patients were divided into observation groups and control groups according to whether or not oral Lianhua Qingwen granules were used. Through data analysis and follow-up, the effectiveness of Lianhua Qingwen in treating patients infected with the Omicron variant of COVID-19 was discussed.

Enrollment

200 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

For patients infected with the Omicron variant, the diagnostic criteria are confirmed cases of COVID-19 and clinical classification according to the diagnostic criteria of Prevention and Control Protocol for COVID-19 (Trial Eighth Edition) issued by the National Health and Construction Commission.
The clinical symptoms were classified as mild or ordinary.
They have been vaccinated against the COVID-19.

Exclusion criteria

Patients receiving antiviral or antibiotic drugs
Severe and critical patients with COVID-19.
Patients with chronic respiratory diseases, bacterial infections of the respiratory system, and other respiratory diseases affecting the study.
Patients with serious primary diseases of the heart, brain, lung, liver, kidney, and hematopoietic systems, as well as mental diseases.
Allergic reaction to Lianhua Qingwen granules.
Excluded patients treated with the same drug as Lianhua Qingwen.